The evolving role of real-world evidence in secondary fracture prevention
- kenashman
- May 13
- 1 min read
UCB 11 April 2025 post by Steve Turley
In osteoporosis research and clinical practice, the value of real-world evidence (RWE) is increasingly acknowledged; but much of its potential remains untapped. By analyzing real-world treatment patterns, RWE provides deeper insights into the effectiveness of osteoporosis treatments. Unlike clinical trials, which operate under controlled conditions, RWE captures the realities of routine clinical practice.
Worldwide, osteoporosis is estimated to cause fractures in a staggering one in three women over the age of 50, and in women over 45 years of age, osteoporosis accounts for more days in hospital than many other diseases, including diabetes, myocardial infarction and breast cancer.
With 71% of patients who sustain fractures related to osteoporosis remaining undiagnosed and untreated, data around treatment journeys is essential to help close the gap. A comprehensive picture of how patients experience care, manage their condition and navigate healthcare systems is lacking.
Highlighting the impact of RWE at WCO-IOF-ESCEO
At the 25th WCO-IOF-ESCEO Congress in Rome, Italy, UCB, its partner, Amgen and investigators from supported investigator-initiated studies, are presenting eight abstracts, further building the body of RWE that can be used to elevate care for those at high risk of fracture.
